Please login to the form below

irritable bowel syndrome

This page shows the latest irritable bowel syndrome news and features for those working in and with pharma, biotech and healthcare.

pain associated with irritable bowel syndrome (IBSs).

NHS could save almost £7bn through its own resources

The report specifically evaluated the savings of three IVD tests - covering suspected heart attacks, pre-eclampsia in pregnancy and diagnosing irritable bowel syndrome (IBS) - if widely used. ... Lastly, IVDs for common bowel condition IBS could save the
Mallinckrodt pays $1.2bn for Sucampo Pharma

Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid
NICE backs Allergan's IBS therapy Truberzi

NICE has recommended routine NHS funding for Allergan's Truberzi, which is the first drug for irritable bowel syndrome with diarrhoea (IBS-D) to pass through its review process.
FDA approves Synergy's constipation drug Trulance

In trials, a once-daily dose of Trulance was more effective than placebo to improve the frequency of bowel movements in patients diagnosed with CIC for at least six months. ... constipation linked to irritable bowel syndrome (IBS).
Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Now, the Canadian company has decided to build up Salix' salesforce to push its flagship brand – Xifaxan (rifaximin) for diarrhoea caused by irritable bowel syndrome – which has been tipped by some

More from news
Approximately 1 fully matching, plus 52 partially matching documents found.

Erectile dysfunction, constipation, vaginal dryness and other laughing matters

An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... This campaign showed doctors suffering from Irritable Disbelief Syndrome (IDS) - a brave move but exactly the perception shift
Taking a lean and careful approach

His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation. ... ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
Can biosimilars live up to the hype?

She is convinced that biosimilars are essential in treating patients with chronic conditions such as rheumatoid arthritis, irritable bowel syndrome and psoriasis, because they provide the same uplift in quality of
Oral biologics delivery still elusive

years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... Among these are Avaxia Biologics, which
Pharma deals during April 2014

associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms. ... Eluxadoline is a first-in-class, locally-acting mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Ironwood appoints Edward Owens to board

irritable bowel syndrome and constipation. “
Ironwood promotes Dr Mark Currie

Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Home based, Senior Medical Writer, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Add my company

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....